Skip to content

13F-HR filed by Casdin Capital, LLC

Casdin Capital, LLC filed this 13F-HR for the quarter ended 2019-12-31, filed 2020-02-14, with 32 holding rows worth $1,087,417,000.

Accession
0001534261-20-000005
Filed
2020-02-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2019

A holdings report, 32 entries on the cover page, a total value of $1,087,417,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,087,417,000 with VALUE read as thousands by filing date, 13F file number 028-17113. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
SAREPTA THERAPEUTICS INC803607100COM670,000$86,457,000thousands by filing date
BLUEBIRD BIO INC09609G100COM970,000$85,118,000thousands by filing date
CODEXIS INC192005106COM5,073,780$81,130,000thousands by filing date
BLUEPRINT MEDICINES CORP09627Y109COM940,000$75,303,000thousands by filing date
MYOKARDIA INC62857M105COM1,005,000$73,249,000thousands by filing date
ALNYLAM PHARMACEUTICALS INC COM02043Q107Stock515,000$59,313,000thousands by filing date
INVITAE CORP46185L103COM3,638,388$58,687,000thousands by filing date
CONSTELLATION PHARMACEUTICALS INC.210373106Common Stock1,212,734$57,132,000thousands by filing date
AUDENTES THERAPEUTICS INC.05070R104Common Stock860,000$51,462,000thousands by filing date
FATE THERAPEUTICS INC31189P102COM2,550,000$49,904,000thousands by filing date
DIANTHUS THERAPEUTICS INC COM55910K108Stock3,098,121$46,968,000thousands by filing date
BIOLIFE SOLUTIONS INC COM NEW09062W204Stock2,468,571$39,941,000thousands by filing date
AGIOS PHARMACEUTICALS INC00847X104COM825,000$39,394,000thousands by filing date
CAREDX INC14167L103COM1,200,000$25,884,000thousands by filing date
GLOBAL BLOOD THERAPEUTICS USD37890U108COM300,000$23,847,000thousands by filing date
DENALI THERAPEUTICS INC COM24823R105Stock1,250,000$21,775,000thousands by filing date
FULCRUM THERAPEUTICS INC359616109COMMON STOCK1,239,285$20,622,000thousands by filing date
ILLUMINA INC452327109COM60,000$19,904,000thousands by filing date
GRITSTONE BIO INC39868T105COM2,160,000$19,375,000thousands by filing date
ALECTOR INC014442107COMMON STOCK1,076,039$18,540,000thousands by filing date
SAGE THERAPEUTICS INC78667J108COM230,000$16,604,000thousands by filing date
GENMARK DIAGNOSTICS INC372309104COM3,365,000$16,186,000thousands by filing date
DECIPHERA PHARMACEUTICALS IN24344T101COM255,000$15,871,000thousands by filing date
VOYAGER THERAPEUTICS INC92915B106COMMON STOCK1,095,075$15,276,000thousands by filing date
ADAPTIVE BIOTECHNOLOGIES CORP COM00650F109Stock463,125$13,857,000thousands by filing date
Gilead Sciences,Inc.375558103COM200,000$12,996,000thousands by filing datecall
SANGAMO THERAPEUTICS INC800677106COM1,455,000$12,178,000thousands by filing date
ORCHARD THERAPEUTICS PLC68570P101ADR820,000$11,275,000thousands by filing date
TWIST BIOSCIENCE CORP90184D100COM300,000$6,300,000thousands by filing date
TURNING PT THERAPEUTICS90041T108COM75,000$4,672,000thousands by filing date
BRISTOL-MYERS SQUIBB CO110122157RIGHT 99/99/99991,500,000$4,515,000thousands by filing date
STOKE THERAPEUTICS INC86150R107COM130,000$3,682,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001534261-20-000005this filing2020-02-14acceptance time not in the bulk data set